Latest Breaking News On - Cilag international - Page 1 : comparemela.com

TAR-210 results show 90 percent recurrence-free survival

Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor.

Comunidad autonoma de catalunaRegion flamandeSan antonioUnited statesEurop urolJanssen pharmaceuticaTanakam sonpavdeClin pharmacolSabine brookmanHenar heviaIndianj urolAstex therapeuticsDrug administrationEuropean medicines agencyNone of janssen cilag internationalEuropean society for medical oncology

Phase 2 data for ERLEADA® ▼(apalutamide) plus androgen

Study highlights opportunity for treatment intensification in this population since approximately 50 percent of patients with high-risk localised prostate.

United statesRegion flamandeSan antonioHenar heviaLuca dezzaniExchange commissionJanssen research developmentAmerican urological association annual meetingSteering committeeJanssen cilag internationalNone of janssen cilag internationalEuropean medicines agencyJanssen cilag international nv incOral presentation sessionUrological association annual meetingSteering committee chair

Johnson & Johnson : receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations

Media contact: Investor contact: .

Region flamandeFrance generalInstitut curieHenar heviaNicolas girardZayn qureshiEuropean medicines agencyJanssen cilag internationalParis saclay universityCommittee for medicinal products human useCilag internationalMedicinal productsHuman useProfessor nicolas girardMedical oncologyThoracic oncology

Johnson & Johnson : CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy

Media contact: Investor contact: .

United statesRegion flamandeEdmond chanJenni mildonCiltacabtagene autoleucelEuropean commission grants conditional approvalLegend biotech united states incJanssen biotech incDrug administrationAmerican society of clinical oncologyEuropean commissionJanssen cilag internationalChinese company legend biotech to develop investigationalAmerican cancer societyCommittee for orphan medicinal productsJanssen research development

Human Trials Archives - Pharmaceutical Business review

Human Trials Archives - Pharmaceutical Business review
pharmaceutical-business-review.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-business-review.com Daily Mail and Mail on Sunday newspapers.

Janssen cilag internationalEuropean medicines agencyCilag international